San Diego, Calif. • 858-436-8600 • www.orexigen.com
Exchange and Ticker: Nasdaq: OREX
Filing Range: 6 million shares @ $11.00 to $13.00
Offering Price: $12.00
Close on First Day: $12.90
Offering Size: $84.00M
Shares Outstanding: 24,860,270M
Underwriter: Merrill Lynch
Co-managers: JMP Securities LLC/ Leerink Swann & Co./ J.P. Morgan
Company Counsel: Latham & Watkins
Manager Counsel: Blank Rome LLP
Auditor: Ernst & Young LLP
Market Capitalization on 4/30/07: $349.29M
Close price at current month end: $14.05
DESCRIPTION
Develops and commercializes drug treatments for obesity therapeutics and other related disorders. The company develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body’s efforts to compensate for weight loss. Competitors include Abbott Laboratories, Alizyme plc, Amylin Pharmaceuticals Inc.,Arena Pharmaceuticals Inc., Merck & Co., Peptimmune Inc., Roche Laboratories Inc., Sanofi-Aventis, and Vivus Inc.
VENTURE BACKERS
Domain Associates, Duke University, Kleiner Perkins Caufield & Byers, Montreux Equity Partners, Morgenthaler Ventures, MPM Capital, Scale Venture Partners, Sofinnova Ventures, Wasatch Venture Fund.
Source: Thomson Financial